HERABLE - HER-2 Status in Gastric and Gastro-Oesophageal Junction Cancer

Head :
Roche Medical Data Center

Last update : 06/29/2022 | Version : 1 | ID : 74137

print
Print
xml
XML

Export to XML

Please choose the format :

pdf
PDF
xml
CSV (Excel)

Export to CSV

What sections do you want to export ?

Métadonnées
Identification
General Aspects
Scientific investigator(s) (Contact)
Collaborations
Funding
Governance of the database
Additional contact
Type of database
Database objective
Population type
Dates
Size of the database
Data
Procedures
Promotion
Access
Select all | Invert selection | No selection

Which version do you want to export ?

French version
send
Send
General
Identification
Detailed name HER-2 Status in Gastric and Gastro-Oesophageal Junction Cancer
Sign or acronym HERABLE
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation ML27940
General Aspects
Medical area Cancer research
Study in connection with Covid-19 No
Pathology (details) Gastric and gastro-oeasophageal junction cancer
Health determinants Medicine
Keywords HERABLE
Scientific investigator(s) (Contact)
Name of the director Roche Medical Data Center
Address 4 cours de l'Ile Seguin - 92650 BOULOGNE-BILLANCOURT
Email data_sharing_france@roche.com
Organization Roche SAS
Collaborations
Participation in projects, networks and consortia No
Funding
Funding status Private
Governance of the database
Sponsor(s) or organisation(s) responsible Roche SAS
Organisation status Private
Presence of scientific or steering committees Yes
Additional contact
Name of the contact https://www.roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html
Main features
Type of database
Type of database Study databases
Study databases (details) Cohort study
Database recruitment is carried out by an intermediary A selection of health institutions and services
Database recruitment is is made on the basis of: Medication(s) taken
Database recruitment is carried out as part of an interventional study No
Database objective
Main objective Primary objective: Positive HER2 status is defined as IHC3+ or IHC2+/ISH+, as per the Herceptin® SPC.

Secondary objectives:
Evaluated according to HER2 status determined by the centralized laboratory
- Describe pathological features of the tumors (assessed locally) according to HER2 status;
- Evaluate concordance between IHC 4B5 and SISH results for each sample;
- Evaluate concordance between HER2 status determined on biopsies and surgical specimens (globally and according to use or not of neoadjuvant chemotherapy);
- Describe expression of the following markers: HER3, HER4, PTEN, cMET, Bcl2, p53.
Inclusion criteria Inclusion criteria:
- Gastric or GEJ adenocarcinoma specimens, regardless of stage, histologically documented (biopsy, surgical specimen, lymph node or distant metastasis);
- Enough tumor material available to allow for the centralized analysis;
- Specimens fixed and embedded in paraffin;
- From a patient who was informed about the study orally and in writing by the oncologist or gastroenterologist, with a signed certificate of no objection.

Exclusion criteria:
- Fixatives not allowed: Bouin's solution.
Population type
Age Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)
Population covered Sick population
Pathology D00 - Carcinoma in situ of oral cavity, oesophagus and stomach
Gender Male
Woman
Geography area National
Data collection
Dates
Date of first collection (YYYY or MM/YYYY) 2012
Date of last collection (YYYY or MM/YYYY) 2014
Size of the database
Size of the database (number of individuals) < 500 individuals
Details of the number of individuals 421
Data
Database activity Data collection completed
Type of data collected Clinical data
Biological data
Clinical data (detail) Medical registration
Details of collected clinical data Validation of inclusion and exclusion criteria - Dates of visits (or data of last contact with the patient) - Demographic - CKD history and evolution - Comorbidities - Most recent clinical and biological data - Previous and/or ongoing CKD treatments - Other specific treatments - Previous and/or ongoing anemia treatments - Treatment with Micera® - Adverses events - Reason for early study discontinuation.
Presence of a biobank No
Health parameters studied Health event/morbidity
Health event/mortality
Health care consumption and services
Care consumption (detail) Medicines consumption
Procedures
Data collection method eCRF
Classifications used CDISC
Quality procedure(s) used GCP/GVP
Participant monitoring Yes
Monitoring procedures Monitoring by contact with the referring doctor
Links to administrative sources No
Promotion and access
Promotion
Access
Dedicated website https://www.roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html
Presence of document that lists variables and coding procedures Yes
Access to aggregated data Access on specific project only
Access to individual data Access on specific project only

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05

View Edit Create here